A low prostate specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer. (March 2023)

• Record Type: Journal Article
• Authors: Fankhauser, Christian D.; Parry, Matthew G.; Ali, Adnan; Cowling, Thomas E.; Nossiter, Julie; Sujenthiran, Arun; Berry, Brendan; Morris, Melanie; Aggarwal, Ajay; Payne, Heather; van der Meulen, Jan; Clarke, Noel W.
• Is Part Of: European journal of cancer. Volume 181(2023)
• Page Start: 70
• Page End: 78
• Publication Date: 2023-03
• Subjects: Prostate cancer -- Prostatectomy -- Radiotherapy -- Brachytherapy -- Androgen deprivation therapy -- Prostate-specific antigen; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2022.12.017
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Objective: The relationship between prostate-specific antigen (PSA) and prostate cancer (PCa) grade was traditionally thought to be linear but recent reports suggest this is not true in high-grade cancers. We aimed to compare the association between PSA and PCa-specific mortality (PCSM) in clinically localised low/intermediate and high-grade PCa. Subjects/patients and methods: Retrospective cohort study using the National Prostate Cancer Audit database in England of men treated with external beam radiotherapy (EBRT), EBRT and brachytherapy boost (EBRT + BT), radical prostatectomy or no radical local treatment between 2014 and 2018. Multivariable competing-risk regression was used to examine the association between PSA, Gleason, and PCSM. Multivariable restricted cubic spline regression was used to explore the non-linear associations of PSA and PCSM. Results: 102, 089 men were included, of whom 71, 138 had low/intermediate-grade and 22, 425 had high-grade PCa. In high-grade, 4-year PCSM was higher with PSA ≤5 than PSA 5.1–10 for men treated with EBRT (hazard ratio 1.96 (95% confidence interval 1.15–3.34) or no radical local treatment (hazard ratio 1.99 (95% confidence interval 1.33–2.98). Restricted cubic spline regression showed that PSA and PCSM have a non-linear association in high-grade but a linear association in low/intermediate-grade PCa. Conclusion: The low-PSA/high-grade combination in M0 PCa treated with EBRT has a higher PCSM than those with high-grade and intermediate PSA levels. In high-grade disease, the PSA association was non-linear; by contrast, low/intermediate-grade had a linear relationship. This confirms a more aggressive biology in low PSA secreting high-grade PCa and a worse outcome following treatment. Highlights: Large dataset describing the prognostic value of prostate-specific antigen (PSA) in localised prostate cancer. In high-grade prostate cancer, a low or high PSA predicts poor outcomes. In low/intermediate-grade prostate cancer, the higher the PSA the worse the outcome. This confirms a more aggressive biology in low PSA secreting high-grade PCa.